Company profile
Pelthos Therapeutics Inc.
AMEX: PTHS · Healthcare · Biotechnology
#575 of 1,422 Healthcare companies by revenue
EA Score
37DFH 48DQ 20GM —SS 43
v0.1 · 55/100 weight · provisional
↑ Piotroski F, market scale · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$27.7M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$43.3M
Employees
92
as of 2026-08-21
Market cap
$92.7M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$16.8M$16.8M2025
Net income-$43.3M-$43.3M2025
Operating income-$32.4M-$32.4M2025
Total assets$130.4M$130.4M2025
Liabilities$91.5M$91.5M2025
Equity$38.9M$38.9M2025
Revenue by segment
Filed disclosures · FY2025
By product
License and Collaboration100%
By geography
Not disclosed.
The read
What is Pelthos Therapeutics Inc.’s revenue?
Pelthos Therapeutics Inc. booked $16.8M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -257.9% net margin.
Peers · Healthcare
Clever Leaves Holdings Inc.——Choom Holdings Inc.——Veru Inc.49DIsodiol International Inc.——Inspire Veterinary Partners, Inc.——Seer, Inc.50DNeighbors
Durham →Key facts
CEOScott Plesha
SectorHealthcare
IndustryBiotechnology
HeadquartersDurham, NC
ExchangeAMEX: PTHS
Employees92
IPO date2025-07-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.